In patients with treatment-resistant hypertension, the procedure has the potential to produce sustained blood pressure reductions for 36 months or longer. 

The procedure reduces inflammation and pain, and allows patients to achieve relief without having to undergo surgery and months of physical therapy during recovery. 

Instylla's Embrace Hydrogel Embolic System minimizes bleeding risks during the embolization of hypervascular tumors in the peripheral arteries.

Ablation therapy used to treat hepatocellular carcinoma requires image guidance, which is usually done via ultrasound, CT or MRI.

New research, published in The American Journal of Cardiology, uncovers widespread variability in provider preference for image guidance during PCI. 

The added indications make the treatment the first Y-90 therapy approved for both unresectable hepatocellular carcinoma and metastatic colorectal cancer of the liver.

A communication error within the system can reportedly cause loss of imaging functionality mid-procedure.